JFG
MRSN

Jefferies Financial Group’s Mersana Therapeutics MRSN Stock Holding History

Jefferies Financial Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,024
Closed -$331K – 1844
2023
Q2 		$331K Buy
+4,024
New +$589K ﹤0.01% 1294

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Jefferies Financial Group's MRSN Position: Q3 2023 in Review

Jefferies Financial Group sold out of Mersana Therapeutics (MRSN) in Q3 2023, closing a stake of 1,599 shares — an estimated $132K sold.

Jefferies Financial Group first reported a position in MRSN in Q2 2023 and held it in 1 quarter. The position peaked at $132K in Q2 2023. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • Jefferies Financial Group reported no remaining Mersana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Jefferies Financial Group sold 1,599 Mersana Therapeutics shares in Q3 2023, an estimated $132K.
  • Jefferies Financial Group first reported a position in Mersana Therapeutics in Q2 2023 and held it in 1 quarter.
  • Jefferies Financial Group's Mersana Therapeutics position peaked at $132K in Q2 2023.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on Jefferies Financial Group's 13F filing for Q3 2023, filed 14 Nov 2023.